Latest Content

Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed/refractory acute myeloid leukemia with mostly low-grade side effects.

It’s been two-and-a-half years since I “rang the bell” on the Oncology ward, signaling that I had ended my chemotherapy treatment.

Wendy and Larry Brooks share their journey with small cell lung cancer, emphasizing the importance of screening, as well as advocacy for patients and caregivers.

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

I usually write about my daughter’s cancer, but my friend’s stage 4 breast cancer journey showed me the limits of strength and the need for help.

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.

Six-year phase 3 follow-up showed adding Loqtorzi to chemotherapy nearly doubled survival for recurrent or metastatic nasopharyngeal cancer.

As I reflect on my lung cancer journey, I look back to the 2018 holiday season, feeling comfortable and at peace.

I attended this year’s Light the Night walk in remembrance of my sister, reflecting on her 11-year battle and enduring identity as a cancer survivor.

This guide features information from diagnosis to treatment of adenocarcinoma of the bladder.

Asian women who do not smoke in Northern California face rising lung cancer rates which are often diagnosed late due to current screening gaps.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.